Statin use significantly reduced the risk of all-cause mortality by 79% compared to no statin use in patients with heart failure with preserved ejection fraction without coronary artery disease.
Observational (n=414)
Yes
Does statin use reduce all-cause mortality in patients with heart failure with preserved ejection fraction without coronary artery disease?
Statin therapy at admission is associated with significantly lower all-cause mortality and heart failure rehospitalization in patients with HFpEF without coronary artery disease.
Effect estimate: HR 0.21 (95% CI 0.06-0.72)
Absolute Event Rate: 8.9% vs 23%
p-value: p=0.014
BACKGROUND: Statins might be associated with improved survival in patients with heart failure with preserved ejection fraction (HFpEF). The effect of statins in HFpEF without coronary artery disease (CAD), however, remains unclear. METHODS AND RESULTS: From the JASPER registry, a multicenter, observational, prospective cohort with Japanese patients aged ≥20 years requiring hospitalization with acute HF and LVEF ≥50%, 414 patients without CAD were selected for outcome analysis. Based on prescription of statins at admission, we divided patients into the statin group (n=81) or no statin group (n=333). We followed them for 25 months. The association between statin use and primary (all-cause mortality) and secondary (non-cardiac death, cardiac death, or rehospitalization for HF) endpoints was assessed in the entire cohort and in a propensity score-matched cohort. In the propensity score-matched cohort, 3-year mortality was lower in the statin group (HR, 0.21; 95% CI: 0.06-0.72; P=0.014). The statin group had a significantly lower incidence of non-cardiac death (P=0.028) and rehospitalization for HF (P<0.001), but not cardiac death (P=0.593). The beneficial effect of statins on mortality did not have any significant interaction with cholesterol level or HF severity. CONCLUSIONS: Statin use has a beneficial effect on mortality in HFpEF without CAD. The present findings should be tested in an adequately powered randomized clinical trial.
Marume et al. (Thu,) conducted a observational in Heart failure with preserved ejection fraction (HFpEF) without coronary artery disease (n=414). Statins vs. No statins was evaluated on All-cause mortality (HR 0.21, 95% CI 0.06-0.72, p=0.014). Statin use significantly reduced the risk of all-cause mortality by 79% compared to no statin use in patients with heart failure with preserved ejection fraction without coronary artery disease.